integrated project mucosal vaccines for poverty-related diseases muvapred muvapred project summary...
TRANSCRIPT
INTEGRATED PROJECTINTEGRATED PROJECT
MUCOSAL VACCINES FOR POVERTY-RELATED DISEASESMUCOSAL VACCINES FOR POVERTY-RELATED DISEASES
MUVAPREDMUVAPREDMUCOSAL VACCINES FOR POVERTY-RELATED DISEASESMUCOSAL VACCINES FOR POVERTY-RELATED DISEASES
MUVAPREDMUVAPRED
Project SummaryProject Summary
Human Immunodeficiency Virus and Human Immunodeficiency Virus and Mycobacterium Mycobacterium
tuberculosistuberculosis enter the human body at mucosal sites. The aim enter the human body at mucosal sites. The aim
of the present project is to develop mucosally delivered of the present project is to develop mucosally delivered
vaccines against HIV and TB which will induce local immunity vaccines against HIV and TB which will induce local immunity
able to neutralise the pathogens at their port of entry and able to neutralise the pathogens at their port of entry and
systemic immunity able to prevent systemic spread of the systemic immunity able to prevent systemic spread of the
infection. The possible development of mucosal vaccines infection. The possible development of mucosal vaccines
against malaria will be also investigated. The trust of the against malaria will be also investigated. The trust of the
project derives from the recent proof of concept that mucosal project derives from the recent proof of concept that mucosal
vaccines are feasible in humans. vaccines are feasible in humans.
While the first trials are performed, new systems to deliver While the first trials are performed, new systems to deliver
mucosal vaccines and basic mechanisms of mucosal immune mucosal vaccines and basic mechanisms of mucosal immune
responses and memory in humans will be studied. This will responses and memory in humans will be studied. This will
allow better understanding of the clinical results and allow better understanding of the clinical results and
optimisation of second generation vaccines to be tested in optimisation of second generation vaccines to be tested in
Developing Countries during the second phase of the project.Developing Countries during the second phase of the project.
Phase I trialsPhase I trialsin EUin EU
Phase I trials inPhase I trials inAfricaAfrica
Vaccine Vaccine candidatescandidates
Antigens AdjuvantsDelivery systems
Pre-clinical testingPre-clinical testing
Mice
Guinea Pigs (TB)
Monkeys
Vaccine Vaccine candidates candidates for EDCTPfor EDCTP
New vaccines for povertyNew vaccines for poverty
MUVAPREDMUVAPRED
Project structureProject structure
Development of new promising vaccine candidates (Subproject 1)
1 2 3 4 5 YEARS
Indicative timelines of the main activities
Development of new promising vaccine candidates
Comparative testing in animal models
Phase I trials in EU with available candidates
Clinical trials in Africa
Phase I clinical trials with new vaccine candidates
Correlates of protection
web site: http://www.mucosalimmunity.org/muvapred/web site: http://www.mucosalimmunity.org/muvapred/
Project coordinator: R. Rappuoli, Chiron Srl Project coordinator: R. Rappuoli, Chiron Srl EC contribution : 15.250.000 EuroEC contribution : 15.250.000 EuroStarting date: 1st December 2003Starting date: 1st December 2003Duration: 5 yearsDuration: 5 yearsParticipants: 24 from 10 countriesParticipants: 24 from 10 countries
ObjectivesObjectives
• Phase I clinical trials in EuropePhase I clinical trials in Europe with the available mucosal antigens against HIV/AIDS and TB (two to three vaccine candidates).
• Second generation, optimised vaccine candidatesSecond generation, optimised vaccine candidates against HIV/AIDS, TB and malaria (antigens, adjuvants, delivery systems).
• Selection of the most promising vaccine candidatesmost promising vaccine candidates by comparative testing in animal models
• Phase I clinical trials in Europe with new vaccine candidatesPhase I clinical trials in Europe with new vaccine candidates developed by the consortium
• Phase I clinical trials in AfricaPhase I clinical trials in Africa with the vaccine candidates that have proven to be safe and immunogenic in the first clinical trials in Europe
ParticipantsParticipantsChiron Italy, Imperial College of Science UK, University of Goteborg Sweden, University of Siena Italy, Institute Pasteur France, Istituto Superiore di Sanità Italy, Institute for Research in Biomedicine CH, Max-Planck-Institute, Germany University Hamburg Germany,Trinity College Dublin Ireland, Serum State Institute Denmark, Consiglio Nazionale delle Ricerche Italy, Istituto Humanitas Milano Italy, German Arthritis Research Center DRFZ Germany, St George’s Vaccine Institute UK, Institute of Microbiology Czech Republic, CAMR UK, University of Florence Italy, Centre-Hospitalier-Universitaire Ignace Deen Guinea, University of Lausanne Switzerland, ALTA Srl Italy, LIONEX Diagnostic & Therapeutics GmbH Germany, INOTECH AG Switzerland
Antigens
WP1
Adjuvants
WP2
Delivery
systems
WP3
Sub-project 1
Vaccine CandidatesVaccine Candidates
Mice
WP4
Guinea
WP5
Monkeys
WP6
Sub-project 2
Animal studiesAnimal studies
Correlates
protection
WP7
GMP
WP8
Phase I
WP9
Sub-project 3
Human studiesHuman studies
MUVAPREDMUVAPRED
Scientific and Administrative Management
COORDINATING TEAM COORDINATING TEAM
STEERING STEERING COMMITTEECOMMITTEE
R. Rappuoli
D. Medaglini
EU Sci. Officer
P. Andersen
G. Dougan
J. Holmgren
S.H.E. Kaufmann
A. Lanzavecchia
D. Lewis T. Lehner
G. Pozzi
R. Rappuoli, Chiron R. Rappuoli, Chiron Project Coordinator
D. Medaglini D. Medaglini University of SienaScientific Manager
A. Tagliabue, ALTA A. Tagliabue, ALTA Administrative Manager
EXTERNAL EXTERNAL ADVISORYADVISORYBOARDBOARD